WealthyVC WealthyVC
  • Home
  • Featured
  • VC Corner: Future IPOs
  • Videos
  • Business News
  • Wealthy Biotech Trader
  • Silicon Valley Insider
  • Radical Consumerist
WealthyVC WealthyVC
  • Home
  • Featured
  • VC Corner: Future IPOs
  • Videos
  • Business News
  • Wealthy Biotech Trader
  • Silicon Valley Insider
  • Radical Consumerist
Oct 22

Investors Shift Focus From Vaccine Stocks to COVID Pill Stocks

  • October 22, 2021
  • admin
  • Business News, Wealthy Biotech Trader

Nearly two years since the COVID-19 pandemic began and almost one year since the various COVID-19 vaccines started to roll out, the investing public is pivoting away from companies developing vaccines to those developing treatments for those who have contracted the virus.

Now that the majority of people who are going to get vaccinated have received their shots, the belief seems to be that the stock prices of vaccine makers like Johnson & Johnson (NYSE: JNJ) and Moderna (NASDAQ: MRNA) have run their course, at least in the short term.

Investors are now turning their attention to other drugmakers, including Atea Pharmaceuticals (NASDAQ: AVIR), Merck & Co. (NYSE: MRK) and Pfizer (NYSE: PFE). These are some of the largest and most well-respected drug makers in the world.  Each of them is pursuing a treatment for COVID-19 in different ways.

Source: Shutterstock

Atea Pharmaceuticals

Atea Pharma (NASDAQ: AVIR) has perhaps the most ambitious plan for COVID-19 treatments among those companies mentioned. The company is partnering with Swiss healthcare giant Roche (SWX: ROG) (OTCQX: RHHBY) to develop an orally administered medication that will treat not only COVID-19 symptoms but also provide increased protection from the virus for those who have not been infected.

The drug is currently known as AT-527 and comes in the form of a pill. It is currently undergoing human trials, which unfortunately produced some disappointing news recently. The latest human trial showed no significant reduction in the viral load of COVID-19 patients.  The company claims that the results may have been skewed because fully vaccinated people were included in the trial. Atea Chief Development Officer Janet Hammond commented:

“Having a healthier and partially vaccinated patient population with largely mild disease has important implications in determining the viral kinetics and may have made it more difficult to evaluate viral efficacy.”

There are further trials scheduled, and the company plans on removing vaccinated people from them in the future. Results from the next batch of trials have been delayed into the second half of 2022 due to these changes. Shares in the company plunged after the negative news, so investors with a healthy risk appetite might capitalize on the weakness in the hopes of more successful results next year.

AVIR Chart by TradingView


Merck

The current leader in bringing a mass-market oral medication for COVID-19 is most likely Merck (NYSE: MRK). The company is partnering with Ridgeback Biotherapeutics to test their antiviral drug Molnupiravir (named for Norse god Thor’s hammer Mjölnir) on COVID-19 patients. Molnupiravir has been in development since 2014, with an initial target of influenza. Fortunately, the antiviral has proven adept at eradicating the COVID-19 virus as well.

In September of last year, Merck began running human trials on the effects of molnupiravir on COVID-19 patients. Earlier this month, the company announced results that could mean a breakthrough for those suffering from the illness. During a year-long study, they found that Molnupiravir reduced hospitalization and death in high-risk patients by as much as 50%. This is far and away the most successful results from a pill-based medication to date.

In June of this year, Merck signed an agreement with the U.S. government to supply the country with $1.2 billion worth of Molnupiravir, should clinical trials prove successful and the FDA grants the drug emergency use authorization.

With promising results in hand, Merck submitted their application to the FDA in mid-October; a decision is expected by November 30th. While the stock is up nearly 10% in the month since the trial results became public, there is likely much more room for it to run, should the FDA rule as expected.

MRK Chart by TradingView


Pfizer

Pfizer (NYSE: PFE) is one of the few companies to roll out a successful COVID-19 on a mass scale ($33 billion in sales thus far), and they’re looking to do the same thing with two different treatments for those who have already been exposed to the virus. One of the treatments is an orally administered pill, while the other is an intravenous injection.

The pill, known as PF-07321332, is meant to be taken in combination with another drug, ritonavir, and is intended to protect those exposed to the virus from becoming infected. The drug has shown promise and is currently undergoing Phase 3 clinical trials, which will conclude in December.

The drug is a bit behind Merck’s in terms of development, but it intends to prevent infection rather than treat those already infected, so it will still have a niche of its own. Should the trials prove to be as successful as expected, sales of PF-07321332 should provide a cushion to what is expected to be a steep falloff in vaccine sales in the future.

PFE Chart by TradingView


Conclusion

While the various COVID-19 vaccines have yet to reach every person on Earth, many people have now gotten their complete shot regimen; other means of staving off the pandemic are needed. If vaccines are the present, COVID-19 pills are the future, and the race is on. As the clinical studies begin to come in and the FDA issues authorization, investors should have all the info they’ll need to make their bets.

Read More:

📙 Top 5 Plant-Based Food Stocks for 2022

📙 Eat Well: The Future of Plant Based Proteins

📙 Trillion Dollar Bipartisan Infrastructure Bill a Boon to Clean Hydrogen Leader PowerTap Hydrogen

Did you enjoy this article? If so, consider signing up for the Wealthy VC Email Newsletter below to start receiving our weekly newsletter featuring the week’s best articles.

Follow Wealthy VC on Social Media: Facebook | Instagram | Twitter | LinkedIn | GETTR

📈Join the Discussion in the Wealthy VC Investor Group

💡Have a Stock Tip or News Story Suggestion? Email us at Invest@WealthyVC.com

Wealthy VC does not hold a position in any of the stocks mentioned in this article.

  • Facebook
  • Twitter
  • Tumblr
  • Pinterest
  • Google+
  • LinkedIn
  • E-Mail

About The Author

Ryan Troup is the Editor in Chief of Wealthy VC and TCI. Ryan has 15+ years of investing experience. Twitter | Email

Related Posts

  • Capitalist Countdown: Wealthy VC’s Top 5 Investing News Stories of the WeekOctober 28, 2021

SEARCH

INSTAGRAM

wealthy_vc

Top 5 Short Squeeze Candidates Investors Should Ke Top 5 Short Squeeze Candidates Investors Should Keep An Eye On 🗜💵(Link in Bio & Story).

As the Likelihood of a #Recession Continues to Increase and Stock Prices Continue to Fall, the Amount of Short Interest in Stocks Throughout the #StockMarket Continues to Rise.

With High Short Interest Also Comes the Potential For a #ShortSqueeze, and We’ve Identified Five #Stocks That Could Be Prime For a Big Squeeze.

📧Subscribe to Our FREE Weekly Email Newsletter Via the 🔗 in Bio.

📲Join Our FREE Text Msg List: Text STOCKS to 1-833-681-1622 to Join.
Capitalist Countdown: Wealthy VC’s Top 5 #Invest Capitalist Countdown: Wealthy VC’s Top 5 #Investing News Stories of the Week 📈📰(Link in Bio & Story).

🔹Musk Talks TWTR Deal, TSLA Layoffs, Trump & Recession.

🔹5 Reasons We Should Have Seen This Market Bubble Bursting.

🔹Crypto Rocked Again By Celsius Debacle Weeks After Terra Collapse.

🔹PowerTap Takes Part in California Hydrogen Summit.

🔹Fed Raises Rates 0.75%, Largest Hike in Nearly 3 Decades.

📧Subscribe to Our FREE Weekly Email Newsletter Via 🔗 in Bio.

📲Join Our FREE Text Msg List: Text STOCKS to 1-833-681-1622 to Join.
Why the Stock Market Likely Hasn’t Bottomed and Why the Stock Market Likely Hasn’t Bottomed and You Shouldn’t “Buy the Dip” Yet 📉🤔(Link in Bio & Story).

The #Investing Community is Fairly Predictable When it Comes to Doling Out Investment Advice During Market Downturns.

Overwhelmingly, the Recommendation Given the Most is to “Buy the Dip” – Your Favorite Stock is Down 10%? #BuyTheDip… But Should You Right Now?

📧Subscribe to Our FREE Weekly Email Newsletter Via 🔗 in Bio.

📲Join Our FREE Text Msg List: Text STOCKS to 1-833-681-1622 to Join.
VIDEO: Elon Musk Talks Twitter Deal, Tesla Layoffs VIDEO: Elon Musk Talks Twitter Deal, Tesla Layoffs, Trump and U.S. Recession at Qatar Economic Forum 🇶🇦💰(Link in Bio & Story).

In His Appearance at the Qatar Economic Forum This Morning, the World’s Richest Man, Elon Musk, Discussed a Myriad of Important Topics, Including the Current Status of His Twitter Deal, Planned Layoffs at Tesla, the Likelihood of a U.S. Recession and the Possibility of Him Supporting Donald Trump in the 2024 U.S. Presidential Election.

📧Subscribe to Our FREE Weekly Email Newsletter Via 🔗in Bio.

📲Join Our FREE Text Msg List: Text STOCKS to 1-833-681-1622 to Join.
PowerTap Takes Part in Hydrogen Leadership Summit PowerTap Takes Part in Hydrogen Leadership Summit in Sacramento, California ☀️⛽️(Link in Bio & Story).

#PowerTap Hydrogen (NEO: MOVE) (OTC: MOTNF) (FRA: 2K6B) President Salim Rahemtulla Moderated a Panel at the #HydrogenLeadershipSummit, Which Included Panelists From Chevron, Nikola, Ballard and Trillium.

📧Subscribe to Our FREE Weekly Email Newsletter Via 🔗 in Bio.

📲Join Our FREE Text Msg List: Text STOCKS to 1-833-681-1622 to Join.
VIDEO: U.S. #Fed Raises Interest Rates By 0.75%, I VIDEO: U.S. #Fed Raises Interest Rates By 0.75%, Its Largest Rate Hike in Nearly Three Decades 🇺🇸💸(Link in Bio & Story).

The Historic #RateHike Comes in Response to Soaring #Inflation, Which Climbed 8.6% in May, the Largest Increase Since 1981.

📧Subscribe to Our FREE Weekly Email Newsletter Via the 🔗 in bio.

📲Join Our FREE Text Msg List: Text STOCKS to 1-833-681-1622 to Join.
#Musk Threatens to Walk Away From Twitter Deal Ove #Musk Threatens to Walk Away From Twitter Deal Over Bot Accounts Dispute 💰🤖(Link in Bio & Story).

The #Tesla CEO Recently Sent #Twitter a Stern Letter Accusing it of Breaching the $44 Billion Agreement
5 Recession-Proof Dividend Stocks to Bolster Your 5 Recession-Proof Dividend Stocks to Bolster Your Portfolio 💵📈(Link in Bio & Story).

With All Signs Pointing to the United States Economy Entering Into a Recession, Investors Should Consider Bolstering Their Portfolios With These Five #Recession-Proof #DividendStocks.

📲 Join Our FREE Text Msg List: Text STOCKS to 1-833-681-1622 to Join.
Social Media Investors See $160 Billion Vanish Aft Social Media Investors See $160 Billion Vanish After Disappointing Snap Earnings 💰📉(Link in Bio & Story).

Investors in the Social Media and Digital Advertising Sectors Got Quite a Shock After #Snap Announced Disappointing Earnings Along With a Reduction in Future Guidance
Is Bitcoin Still a Good Hedge Against Inflation? 💸🤔(Link in Bio & Story).

When High Inflation Began to Rear Its Ugly Head in Late 2021, Many Investors Thought #Bitcoin Would Serve as a Strong Hedge Against #Inflation, Similar to #Gold.

Unfortunately, 2022 Has All But Dashed This Hope, With #BTC Plummeting in Direct Correlation With the Equities Market.
Is Elon Musk’s Twitter Shenanigans Hurting Tesla Is Elon Musk’s Twitter Shenanigans Hurting Tesla Investors? 📉🤔(Link in Bio & Story).

Is #ElonMusk Actually Trying to Buy Twitter?

My sk’s Recent Activity and Comments Regarding the $44 Billion #Twitter Transaction Seem to Indicate That He is Not as Fully Committed to the Acquisition as He Let on a Few Weeks Ago.
This Oil Giant Just Overtook Apple as the World’ This Oil Giant Just Overtook Apple as the World’s Most Valuable Company 🛢📈(Link in Bio & Story).

Just a Few Years Ago, it Would Have Been Absurd to Think That an #Oil Company Would Supplant #Apple as the World’s Most Valuable Company, But What a Difference a Year Can Make.

With Oil Prices Continuing to Rise, Oil Giant Saudi #Aramco Has Seen its Valuation Soar to More Than $2.4 Trillion.
Is #ElonMusk Backing Out of the Twitter Deal? 💸 Is #ElonMusk Backing Out of the Twitter Deal? 💸🤔(Link in Bio & Story).

Recent Events and the Large Decline in #TWTR Stock Have the Market Speculating That the Deal May Not Make it Across the Finish Line, at Least Not at the Currently Agreed Upon $44 Billion Valuation
Bitcoin Hits Two and a Half Year Low Amid Cryptocu Bitcoin Hits Two and a Half Year Low Amid Cryptocurrency Carnage 🪙📉(Link in Bio & Story).

The Correction in the Financial Markets Has Been Significant and Prolonged.

#Bitcoin and the Rest of the #Crypto Market Have Been Feeling the Pain Too, Especially After the Recent Carnage Caused By the TerraUSD Stablecoin Debacle.
Cryptocurrency Luna and Linked “Stablecoin” Te Cryptocurrency Luna and Linked “Stablecoin” TerraUSD Both Collapse After UST Breaks From USD Peg 🪙📉(Link in Bio & Story).

While Most People Have Heard of Cryptocurrency, Their Knowledge of the Burgeoning Industry Ends With #Bitcoin and Possibly Ethereum.

Few Are Aware of Just How Vast the #Crypto Market is, Which Now Boasts Over 12,000 Coins, Including the Lesser-Known Sablecoins, One of Which Just Crashed in Spectacular Fashion.
Twitter Stock Still Trading Below Elon Musk’s Of Twitter Stock Still Trading Below Elon Musk’s Offer Price – Should You Buy?📈🤔(Link in Bio & Story).

It’s Been a Wild Few Months for Twitter Investors – After Losing Half its Value Between October and March, #TWTR Stock Has Rallied, Thanks Largely to the Intervention of #ElonMusk.

However, With Shares of #Twitter Stock Currently Trading Below Musk’s Buyout Offer Price, is This a Signal to Investors to Buy the Stock?
Is It Time to Buy Berkshire Hathaway Stock? 📈🤔(Link in Bio & Story).

Not Even the Oracle of Omaha, #WarrenBuffett is Immune to Market Volatility.

With Shares of Buffett’s Company Berkshire Hathaway Following the Market Into Correction Territory, it’s Time to Ask an Important Question, is it Time to Buy BRK Stock?
Federal Reserve Issues Largest Interest Rate Hike Federal Reserve Issues Largest Interest Rate Hike in a Generation 🇺🇸💸(Link in Bio & Story).

#Inflation is At its Highest Point in Decades, and People Are Not Happy About It.

Neither is #FederalReserve Chairman Jerome Powell, Who Finally Decided to Act on It, With a Historic #RateHike.
Big Tech Earnings Recap – Winners & Losers 💰📈📉(Link in Bio & Story).

Another #BigTech #EarningsSZN is in the Books.

Let’s Recap the Results and Take a Look at This Season’s Winners and Losers.
Capitalist Countdown: Wealthy VC’s Top 5 Investi Capitalist Countdown: Wealthy VC’s Top 5 Investing News Stories of the Week 📈📰(Link in Bio & Story).

Please sit back, relax and enjoy Capitalist Countdown’s top 5 market-moving news stories for the week of April 25th – May 1st, 2022.

🔹#Musk Buys Twitter in $44B Deal, to Take Company Private.

🔹Musk’s #Twitter Deal Spooks #TSLA Investors, Shares Fall.

🔹How Crypto is Creeping Into the World of Pro Sports.

🔹Is Netflix a Buy Following Latest 35% Decline?

🔹Consumer Price Index Sees 8.5% #Inflation, Risk of #Stagflation.
Load More... Follow on Instagram

NEWSLETTER

FEATURED VIDEO

https://www.youtube.com/watch?v=c431f188Ik4

About Us

Wealthy VC features a series of industry-focused Investment articles dedicated to showing everyday Investors new opportunities in rapidly growing, little-known stocks in the stock market’s hottest sectors.

Join Our Newsletter

Contact Us

Invest@WealthyVC.com

Categories

  • Business News
  • Featured
  • Radical Consumerist
  • Silicon Valley Insider
  • Videos
  • Wealthy Biotech Trader

Recent News

  • Here’s How Investors Can Combat Stagflation With These 7 Stocks
  • Rising Interest Rates Slow Home Buying
2021 WealthyVC | Disclaimer